Premium
Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5‐fluorouracil
Author(s) -
Gulati Subhash C.,
Sordillo Peter,
Kempin Sanford,
Reich Lilian,
Magill Gordon B.,
Scheiner Ellen,
Clarkson Bayard
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800501)45:9<2252::aid-cncr2820450906>3.0.co;2-n
Subject(s) - medicine , microangiopathic hemolytic anemia , plasmapheresis , epidermoid carcinoma , mitomycin c , anemia , chemotherapy , carcinoma , gastroenterology , squamous carcinoma , fluorouracil , surgery , immunology , thrombotic thrombocytopenic purpura , platelet , antibody
Two patients with epidermoid carcinoma treated with mitomycin‐C (Mit‐C) and 5‐fluorouracil (5‐FU) developed microangiopathic hemolytic anemia (MAHA), renal failure, and altered mental status. Patient 1 was free of metastatic disease, on maintenance Mit‐C and 5‐FU when MAHA changes appeared. Patient 2 had recurrent carcinoma in the pelvic area when MAHA changes appeared. In both patients, MAHA changes and neurologic function improved after exchange plasmapheresis. This is the first report of epidermoid carcinoma manifesting MAHA changes after chemotherapy. Speculation as to pathogenesis and appropriate therapy are discussed.